Transparency data

Non-tech. summaries 2015: projects on oncology

Projects granted during 2015 that have a primary purpose of basic research: oncology.



This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2015 with a primary purpose of basic research: oncology.

It contains a full list of the 41 projects that were granted.

The projects covered are:

  • analysing the genetic and epigenetic control of cancer (cancer, genetics, epigenetics)

  • helicobacter pylori virulence, immunity and disease (helicobacter pylori, virulence factors, carcinogenesis)

  • models of intestinal and genetically related tumours (colorectal tumours, cancer evolution, genetics)

  • radiation-induced leukaemogenesis (leukaemia, radio-sensitive, bone marrow)

  • investigation of tumourigenic pathways (tumour, oncogene, signalling)

  • new strategies for the diagnosis and treatment of glioma (brain tumour, glioma, diagnosis, treatment)

  • glioblastoma treatment and resistance (cancer, brain, rodent, treatment, resistance)

  • in vivo models of childhood leukaemia (childhood leukaemia, new therapies)

  • in vivo studies of tumour associated fibroblasts (fibroblast, cancer, mouse, genetically modified)

  • experimental cancer chemotherapy (xenograft chemotherapy non-genotoxic)

  • arginine methylation and tumourigenesis (cancer, genetically engineered mice)

  • epigenetics of cell senescence, cancer and ageing (epigenetics, cancer, ageing, mouse models)

  • analysis of stressors, nutrition and ageing in cancer (stress, cancer, treatment, ageing, diagnostics)

  • tumour progression in zebrafish models of cancer (cancer, cell signalling, biosensor, tumour microenvironment, optical projection tomography (OPT))

  • investigating human pancreatic cancer in mice (pancreatic cancer, genes, therapy)

  • analysing cancer metastasis and therapy failure (cancer, cell movement, imaging, metastasis, treatment)

  • elucidating novel actionable mutations in cancer (enzymes, genetics, cancer drivers, drug pathways, tumour-suppressing enzymes)

  • aspects of cancer regulation (cancer, macrophage, dormancy, lncRNAs)

  • cellular and molecular haematopoietic dynamics in health and disease (stem cells, haematopoiesis, transplantation, intravital microscopy, stem cell niche)

  • imaging of cell therapy in tumour models (tumour, cell therapy, imaging)

  • pancreatic cancer – improving our understanding and therapeutic options (pancreatic cancer, therapeutic, genotype/phenotype)

  • targeting the mechanisms of tumour vascularisation (cancer, metastasis, tumour stroma, angiogenesis, therapy)

  • defining mechanisms of cancer progression and dissemination (cancer, metastasis, microenvironment, imaging)

  • assessment of tumour initiation and metastatic spread (cancer, metastasis, drugs, endocrine resistance)

  • RUNX1 functions in normal tissues and cancers (haematopoiesis, leukaemia, cancer, reprogramming)

  • cytokine signalling in development and disease (TGF-13 superfamily signalling, transcription, cancer, embryonic development, signal transduction)

  • NKT cells and related immunity in health and disease (cancer obesity NKT (cells) immunotherapy)

  • signalling pathways in cancer (cancer, protein kinase, protein phosphatise)

  • mouse models of prostate cancer initiation and progression (cancer, prostate, tumour-initiating cells, metastasis, therapy)

  • characterisation of cellular heterogeneity in ovarian cancer (stem cells, xenotransplantation, cancer, lineage- tracing)

  • mouse models of KRAS-driven cancer progression & therapy (lung cancer, oncogene, metastasis, therapy)

  • inflammation and viral tumourigenesis (EBV, cancer, chronic inflammation, anti-oxidant)

  • mouse models of human cancer (cancer, GEMS, therapy, transplantation)

  • investigating epithelial cancer in vivo (colorectal cancer, pancreatic cancer, therapy)

  • cancer imaging and drug development (cancer, imaging, diagnosis, early response, drug development)

  • p53-family in physiology and cancer (cancer, aging, development, metabolism)

  • novel functions of p53 mutations in tumour progression (tumours, mutant p53, RCP, engulfment)

  • combining immunotherapy with current cancer treatments (cancer, oncolytic virus, magnetic particles, MRI, macrophages)

  • validation of tumour vascular targets and associated therapies (angiogenesis, cancer, vascular targets)

  • models advancing knowledge and treatment of paediatric brain cancer (paediatric, brain, cancer, treatment, biology)

  • evaluation of novel drug formulations in pancreatic cancer (cancer, drugs, nanotechnology, imaging, targeting)